Xenon Pharmaceuticals announced its Phase 3 X-TOLE2 study of Azetukalner met the primary endpoint in focal onset seizures, with the company calling it one of the strongest efficacy signals ever in a pivotal trial. Shares jumped ~48% in pre-market trading. The result materially de-risks the program and substantially increases the likelihood of regulatory approval and commercial value for Xenon, driving the sharp stock re-rating.
Xenon Pharmaceuticals announced its Phase 3 X-TOLE2 study of Azetukalner met the primary endpoint in focal onset seizures, with the company calling it one of the strongest efficacy signals ever in a pivotal trial. Shares jumped ~48% in pre-market trading. The result materially de-risks the program and substantially increases the likelihood of regulatory approval and commercial value for Xenon, driving the sharp stock re-rating.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment
